Press Releases Guardant Health, Inc.

Stocks

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 10/06/2026 BST			5-day change	1st Jan Change
130.70 ^USD	+0.45%		+2.89%	+27.96%

06-09	Guardant Health Insider Sold Shares Worth $12,629,969, According to a Recent SEC Filing	MT
06-02	Evercore ISI Upgrades Guardant Health to Outperform From In Line, Adjusts PT to $160 From $95	MT

Press Releases

05-28	Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting	BU
05-27	American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines	BU
05-20	FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint	BU
05-18	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05-13	Guardant Health : Corporate Responsibility Report 2026	PU
05-08	Guardant Health : Q1 2026 Earnings Call	PU
05-08	Guardant Health : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05-07	Guardant Health: Q1 Earnings Snapshot	AQ
05-07	Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance	BU
05-06	Guardant Health Receives FDA Approval for Guardant360(R) CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations	AQ
05-04	Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations	BU
04-30	Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform	BU
04-29	Guardant Health to Participate in Upcoming Investor Conferences	BU
04-16	Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026	BU
03-30	Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan	BU
03-24	Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data	PR
03-18	Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026	BU
03-16	Guardant Health : Audit Committee Charter (Audit Committee Charter Feb 2026 c5df54)	PU
03-16	New Guardant Health, Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare	AQ
03-16	Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership	BU
03-13	New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare	BU
03-10	Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics	BU
03-04	Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America	BU
03-03	Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened	BU
02-27	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU